Camp4 Therapeutics (CAMP) Net Income towards Common Stockholders (2023 - 2026)
Camp4 Therapeutics (CAMP) reported Net Income towards Common Stockholders of -$12.2 million for Q1 2026, up 10.49% on a YoY basis from -$11.1 million in Q1 2025, and up 5.6% sequentially from -$12.9 million in Q4 2025.
Camp4 Therapeutics (CAMP) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Camp4 Therapeutics (CAMP) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$12.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 10.49% year-over-year to -$12.2 million; the trailing twelve-month figure through Mar 2026 stood at -$59.4 million (up 8.34% YoY), and the FY2025 full-year result was -$126.5 million, down 8.44% from the prior year.
- Net Income towards Common Stockholders grew to -$12.2 million in Q1 2026, from -$12.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$12.2 million in Q1 2026 to a low of -$23.8 million in Q3 2024.
- A 4-year average of -$14.9 million and a median of -$13.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders plunged 91.67% in 2024 and soared 40.68% in 2025, its largest moves.
- Tracing CAMP's Net Income towards Common Stockholders over 4 years: stood at -$13.4 million in 2023, then retreated by 6.88% to -$14.3 million in 2024, then climbed by 9.44% to -$12.9 million in 2025, then climbed by 5.6% to -$12.2 million in 2026.
- Business Quant data shows CAMP's Net Income towards Common Stockholders at -$12.2 million in Q1 2026, -$12.9 million in Q4 2025, and -$14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Camp4 Therapeutics | 195.78 Mn | 195.78 Mn | - | -12.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.22 Mn |
| Dec 31, 2025 | -12.94 Mn |
| Sep 30, 2025 | -14.10 Mn |
| Jun 30, 2025 | -20.13 Mn |
| Mar 31, 2025 | -13.65 Mn |
| Dec 31, 2024 | -14.29 Mn |
| Sep 30, 2024 | -23.78 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -13.58 Mn |
| Dec 31, 2023 | -13.37 Mn |
| Sep 30, 2023 | -12.40 Mn |